

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

## **RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

### **RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

Reference is made to the section headed “Report of the Directors – Directors” in the 2022 annual report of Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) published on 29 March 2023, in which it was mentioned that, in compliance with the Company’s articles of association, Mr. Mauffrey Benoit Jean Marie (“**Mr. Mauffrey**”) would retire by rotation at the Company’s annual general meeting held on 9 June 2023 (the “**AGM**”) and would not offer himself for re-election as part of the renewal process of the board (the “**Board**”) of directors of the Company (the “**Directors**”).

As a result of the aforesaid retirement by rotation, the Board announces that, Mr. Mauffrey retired as an independent non-executive Director at the conclusion of the AGM. Upon his retirement, he ceased to be a member of the audit committee, remuneration committee, nomination committee and corporate governance committee of the Company with effect from the conclusion of the AGM.

Mr. Mauffrey confirmed that he has no disagreement with the Board and there are no other matters relating to his retirement that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Mr. Mauffrey has demonstrated dedication, diligence and conscientiousness since he joined the Board on 13 June 2001. The Board would like to take this opportunity to express its sincere gratitude to Mr. Mauffrey for his ongoing valuable, professional and independent opinions and for his outstanding contribution to the high-quality and sustainable development of the Company.

## APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is also pleased to announce that, with effect from the conclusion of the AGM, Mr. Yan Man Sing Frankie (“**Mr. Yan**”) has been appointed as an independent non-executive Director and a member of the audit committee, remuneration committee, nomination committee and corporate governance committee of the Company.

The biography of Mr. Yan is set out below:

**Mr. Yan Man Sing Frankie**, aged 65, has over 30 years of experience in auditing, financial management, corporate governance and corporate financial advisory with ample experience in the listing of H shares and merger and acquisition transactions. He is currently a principal and a responsible officer of an investment banking corporation licensed by the Securities and Futures Commission, and one of the founders of a think-tank which regularly gives suggestions on local public policies and two medical devices research institutes in Hong Kong. He started his career in an international accounting firm for over 8 years including a secondment to its London office for 1.5 years. Mr. Yan obtained a master’s degree in finance and investment management from the University of Salford in the United Kingdom. He is a fellow member of the Hong Kong Institute of Certified Public Accountants.

The Board believes that Mr. Yan will generate significant contribution to the Company and the Shareholders as a whole with his extensive experience and valuable knowledge in financial management and corporate governance.

In accordance with the appointment letter entered into between Mr. Yan and the Company, Mr. Yan will be appointed as an independent non-executive director of the Company with effect from 9 June 2023 and expiring on 29 September 2024, determinable by either party serving not less than one month’s written notice on the other, and Mr. Yan’s appointment is subject to retirement by rotation and re-election and other related provisions as stipulated in the articles of association of the Company and the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). Mr. Yan is entitled to a fixed remuneration of HK\$220,000 per year, which is determined by the Board with reference to the recommendation from the remuneration committee of the Company, based on his background, qualification, experience, and the estimated time to be spent by Mr. Yan for his duties as an independent non-executive Director.

Save as disclosed above, as at the date of this announcement, Mr. Yan:

- (i) has not held any other major appointments and qualifications;
- (ii) does not hold any directorships in other public companies listed on any securities market in Hong Kong or overseas in the last three years;

- (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (which have the meaning ascribed to them under the Listing Rules) of the Company;
- (iv) does not hold other positions in the Company or the Group; and
- (v) is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Yan confirmed that there is no other information that should be disclosed pursuant to any of the requirement under Rule 13.51(2) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders in connection with the appointments of Mr. Yan.

The Board would like to take this opportunity to welcome Mr. Yan in joining the Board.

On behalf of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 9 June 2023

*Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Ms. Yeow Mee Mooi and Mr. Yan Man Sing Frankie.*